📜5-Azido-2-[2-(Dimethylamino)Ethyl]Benzo[de]Isoquinoline-1,3-Dione置于硫化氢体系中,化学反应生成 氨萘非特 参考文献:Hydrogen Sulfide Triggered Molecular Agent For Imaging And Cancer Therapy 标题:Hydrogen Sulfide Triggered Molecular Agent For Imaging And Cancer Therapy 摘要:我们开发了一种可激活的分子药剂pnf,由细胞内溶酶体中的h2S触发,释放治疗药物amonafide,该药物可以从溶酶体逃逸进入细胞核,诱导癌细胞的自噬. DOI:10.1039/d0Cc07982K
专利号:US-12391691-B2 优先权日:2018-11-16 标题:Synthesis of key intermediate of KRAS G12C inhibitor compound 发明人:PARSONS ANDREW THOMAS; COCHRAN BRIAN MCNEIL; POWAZINIK IV WILLIAM; CAPORINI MARC ANTHONY 权利人:AMGEN INC 摘要:The present invention relates to an improved, efficient, scalable process to prepare intermediate compounds, such as compound 5M, having the structure n nuseful for the synthesis of compounds that target KRAS G12C mutations, such as
专利号:US-2025206736-A1 优先权日:2019-11-14 标题 :Synthesis of kras g12c inhibitor compound 发明人:CORBETT MICHAEL THOMAS; CAILLE SEBASTIEN 权利人:AMGEN INC 摘要:The present disclosure relates to an improved, efficient, scalable process to prepare intermediate compounds, such as 2-isopropyl-4-methylpyridin-3-amine, useful for the synthesis of compounds, such as Compound 9, for the treatment of KRAS G12C mutated cancers.
专利号:WO-2017100796-A1 优先权日:2015-12-11 标 题 :Modulation of globoseries glycosphingolipid synthesis and cancer biomarkers 发明人:WONG CHI-HUEY; HSU TSUI-LING; WU CHUNG-YI; CHEUNG SARAH K C; CHUANG PO-KAI 权利人:SINACA ACAD; WONG CHI-HUEY; HSU TSUI-LING 摘要:The present disclosure relates to methods and compositions which can modulate the globoseries glycosphingolipid synthesis. Particularly, the present disclosure is directed to glycoenzyme inhibitor compound and compositions and methods of use thereof that can modulate the synthesis of globoseries glycosphingolipid SSEA-3/SSEA-4/GloboH in the biosynthetic pathway; particularly, the glycoenzyme inhibitors target the alpha-4GalT; beta- 4GalNAcT-I; or beta-3GalT-V enzymes in the globoseries synthetic pathway. Additionally, the present disclosure is also directed to vaccines, antibodies, and/or immunogenic conjugate compositions targeting the SSEA-3/SSEA-4/GLOBO H associated epitopes (natural and modified) which elicit antibodies and/or binding fragment production useful for modulating the globoseries glycosphingolipid synthesis. Moreover, the present disclosure is also directed to the method of using the compositions described herein for the treatment or detection of hyperproliferative diseases and/or conditions. Furthermore, the instant disclosure also relates to cancer stem cell biomarkers for disgnostic and therapeutic uses.
专利号:US-2017283878-A1 优先权日:2015-12-11 标题:Modulation of globoseries glycosphingolipid synthesis and cancer biomarkers 发明人:WONG CHI-HUEY; WU CHUNG-YI; CHEUNG SARAH K C; CHUANG PO-KAI; HSU TSUI-LING 权利人:ACADEMIA SINICA 摘要:The present disclosure relates to methods and compositions which can modulate the globoseries glycosphingolipid synthesis. Particularly, the present disclosure is directed to glycoenzyme inhibitor compound and compositions and methods of use thereof that can modulate the synthesis of globoseries glycosphingolipid SSEA-3/SSEA-4/GloboH in the biosynthetic pathway; particularly, the glycoenzyme inhibitors target the alpha-4GalT; beta-4GalNAcT-I; or beta-3GalT-V enzymes in the globoseries synthetic pathway. Additionally, the present disclosure is also directed to vaccines, antibodies, and/or immunogenic conjugate compositions targeting the SSEA-3/SSEA-4/GLOBO H associated epitopes (natural and modified) which elicit antibodies and/or binding fragment production useful for modulating the globoseries glycosphingolipid synthesis. Moreover, the present disclosure is also directed to the method of using the compositions described herein for the treatment or detection of hyperproliferative diseases and/or conditions. Furthermore, the instant disclosure also relates to cancer stem cell biomarkers for diagnostic and therapeutic uses.
专利号:US-9051302-B2 优先权日:2008-01-15 标 题 :Synthesis of resorcylic acid lactones useful as therapeutic agents 发明人:WINSSINGER NICOLAS; BARLUENGA SOFIA; KARPLUS MARTIN 权利人:WINSSINGER NICOLAS; BARLUENGA SOFIA; KARPLUS MARTIN; UNIV STRASBOURG 摘要:Disclosed are macrocyclic compounds of formulae I, I′, II, II′, III, III′, IV, and V, which are analogs of the pochonin resorcylic acid lactones, pharmaceutical compositions comprising the compounds, and methods and uses comprising the compounds for the treatment of diseases mediated by kinases and Heat Shock Protein 90 HSP90.
专利号:US-6787668-B2 优先权日:2000-04-13 标 题 :2-amino-4,5 heptenoic acid derivatives useful as nitric oxide synthase inhibitors 发明人:PITZELE BARNETT S; SIKORSKI JAMES A; WEBBER RONALD KEITH 权利人:PHARMACIA CORP 摘要:The present invention is directed to a compound of formula I:or a pharmaceutically acceptable salt thereof, wherein:R1 is selected from the group consisting of H and methyl; andR2 is selected from the group consisting of H and methyl.The compounds possess useful nitric oxide synthetase inhibiting activity, and are expected to be useful in the treatment or prophylaxis of a disease or condition in which the synthesis or over synthesis of nitric oxide forms a contributory part.
1: Allen SL, Lundberg AS. Amonafide: a potential role in treating acute myeloid leukemia. Expert Opin Investig Drugs. 2011 Jul;20(7):995-1003. doi: 10.1517/13543784.2011.585756. Epub 2011 May 19. 35(176):264-274. doi: 10.24976/Discov.Med.202335176.27. 5(1):17-26. doi: 10.1586/ehm.11.68. 32(3):465-73. doi: 10.1016/j.leukres.2007.07.017. Epub 2007 Sep 10. 11:2339-2348. doi: 10.2147/CMAR.S177623. 6: Zhao J, Lu M, Lai H, Lu H, Lalevée J, Barner-Kowollik C, Stenzel MH, Xiao P. Delivery of Amonafide from Fructose-Coated Nanodiamonds by Oxime Ligation for the Treatment of Human Breast Cancer. Biomacromolecules. 2018 Feb 12;19(2):481-489. doi: 10.1021/acs.biomac.7b01592. Epub 2018 Jan 23. 19(1):23-36. doi: 10.1097/CAD.0b013e3282f00e17. 29(4 Pt 2):596-600. 13(3):741-7. doi: 10.1200/JCO.1995.13.3.741. 53(10 Suppl):2304-8. 23(2):223-9. doi: 10.1093/nar/23.2.223.
合成参考文献
参考文献:10.1517/13543784.2011.585756 摘要:Allen SL, Lundberg AS. Amonafide: a potential role in treating acute myeloid leukemia. Expert Opinion on Investigational Drugs. 2011 May 19;20(7):995–1003. doi: 10.1517/13543784.2011.585756. 参考文献:10.1007/s10895-015-1683-1 摘要:Nayab PS, Pulaganti M, Chitta SK, Abid M, Uddin R. Evaluation of DNA Binding, Radicals Scavenging and Antimicrobial Studies of Newly Synthesized N-Substituted Naphthalimides: Spectroscopic and Molecular Docking Investigations. Journal of Fluorescence. 2015 Oct 13;25(6):1905–20. doi: 10.1007/s10895-015-1683-1. 参考文献:10.1021/acs.jmedchem.6b01846 摘要:Dai F, Li Q, Wang Y, Ge C, Feng C, Xie S, He H, Xu X, Wang C. Design, Synthesis, and Biological Evaluation of Mitochondria-Targeted Flavone-Naphthalimide-Polyamine Conjugates with Antimetastatic Activity. J Med Chem. 2017 Mar 09;60(5):2071–83. doi: 10.1021/acs.jmedchem.6b01846. 参考文献:10.1016/0090-8258(92)90261-g 摘要:Gallion HH, Liu PY, Alberts DE, O'Toole RV, O'Sullivan J, Mills G, Smith HO, Hynes HE. Phase II trial of amonafide in previously treated patients with advanced ovarian cancer: a Southwest Oncology Group study. Gynecol Oncol. 1992 Aug;46(2):230–2. doi: 10.1016/0090-8258(92)90261-g. 参考文献:10.1007/bf00873125 摘要:Perez RP, Nash SL, Ozols RF, Comis RL, O'Dwyer PJ. Phase II study of amonafide in advanced and recurrent sarcoma patients. Invest New Drugs. 1992 Jul;10(2):99–101. doi: 10.1007/bf00873125.